Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Complementary Medicine and Therapies
Published in: BMC Complementary Medicine and Therapies 1/2023

Open Access 01-12-2023 | Diabetic Nephropathy | Research

Shenkang protects renal function in diabetic rats by preserving nephrin expression

Authors: Zhihui Qu, Biyao Wang, Yingli Jin, Qingfei Xiao, Ying Zhao, Danning Zhao, Liming Yang

Published in: BMC Complementary Medicine and Therapies | Issue 1/2023

Login to get access

Abstract

Background

Shenkang injection has been used clinically to lower creatinine levels. This study explored the mechanism of Shenkang injection on protecting kidney function from hyperglycemia-mediated damage.

Methods

This study utilized a STreptoZotocin (STZ)-induced rat model of diabetes. In total, 60 rats were randomized into either the control group (n = 15) injected with vehicle or treatment group (n = 45) injected with STZ to induce hyperglycemia. Eight weeks after diabetes onset, diabetic rats were further randomized to receive different treatments for 4 consecutive weeks, including vehicle (diabetic nephropathy group, n = 15), Shenkang (n = 15), or Valsartan (n = 15). At 12 weeks, a series of urine and blood measures were examined and damage to the kidney tissue was examined using histology. Expression of nephrin and transforming growth factor-β1 (TGF-β1) were characterized using immunohistochemistry and Western blot.

Results

Compared to the control group, rats in the diabetic nephropathy group showed significant kidney damage demonstrated by high kidneyindex, high levels of urinary albumin, albumin/creatinine ratio (ACR), blood urea nitrogen as well as histological evidence. Shenkang injection significantly improved kidney function in the diabetic rats by decreasing kidney index, ACR, and serum creatinine. Shenkang treatment also mitigated kidney damage, improved nephrin expression, and decreased TGF-β1 expression in the kidneys.

Conclusions

Shenkang treatment protected renal function in diabetic rats by increasing nephrin expression, which protects diabetic rats from hyperglycemia-mediated kidney damage.
Appendix
Available only for authorised users
Literature
1.
Magliano DJ, Boyko EJ, committee IDFDAtes. IDF Diabetes Atlas. In: Idf diabetes atlas. Brussels: International Diabetes Federation © International Diabetes Federation, 2021.; 2021.
2.
Umanath K, Lewis JB. Update on Diabetic Nephropathy: Core Curriculum 2018. Am J Kidney Dis. 2018;71:884–95.CrossRefPubMed
3.
4.
Shankland SJ. The podocyte’s response to injury: role in proteinuria and glomerulosclerosis. Kidney Int. 2006;69:2131–47.CrossRefPubMed
5.
KDOQI Clinical Practice Guideline for Diabetes and CKD. 2012 Update. Am J Kidney Dis. 2012;60:850–86.CrossRef
6.
Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369:1892–903.CrossRefPubMed
7.
Anders HJ, Huber TB, Isermann B, Schiffer M. CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease. Nat Rev Nephrol. 2018;14:361–77.CrossRefPubMed
8.
Li X, Xu Z, Ji L, Guo L, Liu J, Feng K, et al. Direct medical costs for patients with type 2 diabetes in 16 tertiary hospitals in urban China: a multicenter prospective cohort study. J Diabetes Investig. 2019;10:539–51.CrossRefPubMed
9.
10.
Wolf G, Ziyadeh FN. Cellular and molecular mechanisms of proteinuria in diabetic nephropathy. Nephron Physiol. 2007;106:p26–31.CrossRefPubMed
11.
Huang H, You Y, Lin X, Tang C, Gu X, Huang M, et al. Inhibition of TRPC6 Signal Pathway alleviates Podocyte Injury Induced by TGF-β1. Cell Physiol Biochem. 2017;41:163–72.CrossRefPubMed
12.
Chang AS, Hathaway CK, Smithies O, Kakoki M. Transforming growth factor-β1 and diabetic nephropathy. Am J Physiol Renal Physiol. 2016;310:F689–f96.CrossRefPubMed
13.
Liu J, Zhang YD, Chen XL, Zhu XL, Chen X, Wu JH, et al. The protective effect of the EP2 receptor on TGF-β1 induced podocyte injury via the PI3K / akt signaling pathway. PLoS ONE. 2018;13:e0197158.CrossRefPubMedPubMedCentral
14.
Liu M, Park J, Wu X, Li Y, Tran Q, Mun K, et al. Shen-Kang protects 5/6 nephrectomized rats against renal injury by reducing oxidative stress through the MAPK signaling pathways. Int J Mol Med. 2015;36:975–84.CrossRefPubMedPubMedCentral
15.
Xu T, Zuo L, Sun Z, Wang P, Zhou L, Lv X, et al. Chemical profiling and quantification of ShenKang injection, a systematic quality control strategy using ultra high performance liquid chromatography with Q exactive hybrid quadrupole orbitrap high-resolution accurate mass spectrometry. J Sep Sci. 2017;40:4872–9.CrossRefPubMed
16.
Jiang X, Zhou L, Zuo L, Wang X, Shi Y, Du X, et al. Pharmacokinetics and Metabolism Research of Shenkang injection in rats based on UHPLC-MS/MS and UHPLC-Q-Orbitrap HRMS. Drug Des Devel Ther. 2020;14:1837–50.CrossRefPubMedPubMedCentral
17.
Guan Y, Wu XX, Duan JL, Yin Y, Guo C, Wei G, et al. Effects and mechanism of combination of Rhein and Danshensu in the treatment of chronic kidney disease. Am J Chin Med. 2015;43:1381–400.CrossRefPubMed
18.
Zou JJ, Zhou XT, Chen YK, Liu JL, Wang C, Ma YR, et al. A review on the efficacy and mechanism of action of Shenkang injection against chronic kidney disease. Biomed Pharmacother. 2020;132:110833.CrossRefPubMed
19.
Wu X, Guan Y, Yan J, Liu M, Yin Y, Duan J, et al. ShenKang injection suppresses kidney fibrosis and oxidative stress via transforming growth factor-β/Smad3 signalling pathway in vivo and in vitro. J Pharm Pharmacol. 2015;67:1054–65.CrossRefPubMed
20.
Zhang YU, Zhou N, Wang H, Wang S, He J. Effect of Shenkang granules on the progression of chronic renal failure in 5/6 nephrectomized rats. Exp Ther Med. 2015;9:2034–42.CrossRefPubMedPubMedCentral
21.
Xu S, Lv Y, Zhao J, Wang J, Zhao X, Wang S. Inhibitory effects of Shenkang injection and its main component emodin on the proliferation of high glucose–induced renal mesangial cells through cell cycle regulation and induction of apoptosis. Mol Med Rep. 2016;14:3381–8.CrossRefPubMed
22.
Yang JJ, Mao ZM, Wan YG, Wu W, Huang YR, Shi G, et al. [Effects and mechanisms of Shenkang injection promoting extracellular matrix degradation via regulating ERK1/2/MMPs signaling pathway in renal failure rats]. Zhongguo Zhong Yao Za Zhi. 2016;41:3805–13.PubMed
23.
Wang WW, Liu YL, Wang MZ, Li H, Liu BH, Tu Y, et al. Inhibition of renal tubular epithelial mesenchymal transition and endoplasmic reticulum Stress-Induced apoptosis with Shenkang Injection attenuates Diabetic Tubulopathy. Front Pharmacol. 2021;12:662706.CrossRefPubMedPubMedCentral
24.
Li T, Shi P, Shi X, Sun P. Pharmacokinetics of astragaloside IV and rhein in normal and chronic nephrotic rats after intravenous administration of Shenkang Injection. Drug Evaluation Research. 2021;44:695–702.
25.
Miao H, Cao G, Wu XQ, Chen YY, Chen DQ, Chen L, et al. Identification of endogenous 1-aminopyrene as a novel mediator of progressive chronic kidney disease via aryl hydrocarbon receptor activation. Br J Pharmacol. 2020;177:3415–35.CrossRefPubMedPubMedCentral
26.
Qi MY, Wang XT, Xu HL, Yang ZL, Cheng Y, Zhou B. Protective effect of ferulic acid on STZ-induced diabetic nephropathy in rats. Food Funct. 2020;11:3706–18.CrossRefPubMed
27.
Levine TR, Hullet CR. Eta Squared, partial Eta Squared, and Misreporting of Effect size in Communication Research. Hum Commun Res. 2002;28:612–25.CrossRef
28.
Tomczak M, Tomczak E. The need to report effect size estimates revisited. An overview of some recommended measures of effect size. Trends Sport Sci. 2014;21:19–25.
29.
Team RC. R: a language and environment for statistical computing. Vienna, Austria: Foundation for Statistical Computing; 2019.
30.
Welsh GI, Saleem MA. Nephrin-signature molecule of the glomerular podocyte? J Pathol. 2010;220:328–37.CrossRefPubMed
31.
Benigni A, Gagliardini E, Tomasoni S, Abbate M, Ruggenenti P, Kalluri R, et al. Selective impairment of gene expression and assembly of nephrin in human diabetic nephropathy. Kidney Int. 2004;65:2193–200.CrossRefPubMed
32.
Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes. 2005;54:1626–34.CrossRefPubMed
33.
Loeffler I, Wolf G. Transforming growth factor-β and the progression of renal disease. Nephrol Dial Transplant. 2014;29(Suppl 1):i37–i45.CrossRefPubMed
Metadata
Title
Shenkang protects renal function in diabetic rats by preserving nephrin expression
Authors
Zhihui Qu
Biyao Wang
Yingli Jin
Qingfei Xiao
Ying Zhao
Danning Zhao
Liming Yang
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2023
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/s12906-023-04078-6

Other articles of this Issue 1/2023

BMC Complementary Medicine and Therapies 1/2023 Go to the issue

Research article

Mechanisms of Rostellularia procumbens (L.) Nees on treating chronic glomerulonephritis explored by network pharmacology, RNA-seq, and in vitro experiments

Research

Exploring the antibacterial, antidiabetic, and anticancer potential of Mentha arvensis extract through in-silico and in-vitro analysis

Research

Afzelin induces immunogenic cell death against lung cancer by targeting NQO2

Research

Panax quinquefolius saponins combined with dual antiplatelet therapy enhanced platelet inhibition with alleviated gastric injury via regulating eicosanoids metabolism

Research

Efficacy and safety of topical 0.1% cannabidiol for managing recurrent aphthous ulcers: a randomized controlled trial

Retraction Note

Retraction Note: Astragalin alleviates cerebral ischemia-reperfusion injury by improving anti-oxidant and anti-inflammatory activities and inhibiting apoptosis pathway in rats